Who Paid My Doc
Jamie Weisman
Atlanta, GA Medical Doctor
NPI 1033131610 CMS profile 47072
5730 Glenridge Dr, Suite T-100, Atlanta, GA 30328
General payments
$620,378
Research payments
$82,843
Ownership & investment interest
$0
Research they led as principal investigator
$4,303,333
Through program year 2025, Jamie Weisman of Atlanta, GA is reported in the CMS Open Payments database as having received $620,378 across 1,389 general payments and $82,843 in research payments paid to them. Separately, studies naming them as principal investigator received $4,303,333 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
11 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $227,477 | 278 | |
| 2024 | General | $149,930 | 284 | |
| 2023 | General | $26,913 | 175 | |
| 2023 | Research | $8,909 | 4 | |
| 2022 | General | $22,047 | 148 | |
| 2022 | Research | $6,312 | 5 | |
| 2021 | General | $39,808 | 106 | |
| 2020 | General | $47,190 | 116 | |
| 2020 | Research | $45,081 | 14 | |
| 2019 | General | $107,014 | 282 | |
| 2019 | Research | $22,541 | 21 |
Beside peers
- Jamie Weisman
- Georgia median
- Middle half of Georgia
- National median
In program year 2025, general payments to Jamie Weisman were reported at $227,477. Among 34,129 Georgia profiles paid that year, the median was $183 and the middle half received between $50 and $656.
Show as a table
| Year | Jamie Weisman | Georgia median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $107,014 | $177 | $54–$648 | $163 |
| 2020 | $47,190 | $130 | $38–$432 | $114 |
| 2021 | $39,808 | $141 | $38–$499 | $132 |
| 2022 | $22,047 | $164 | $45–$574 | $149 |
| 2023 | $26,913 | $177 | $49–$620 | $160 |
| 2024 | $149,930 | $177 | $51–$638 | $164 |
| 2025 | $227,477 | $183 | $50–$656 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 36 drugsPart D claims
1,477
Drug cost
$2,102,969
Branded share of claims
24.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | Brand | 25 | $332,861 | |
| Skyrizi Pen Risankizumab-Rzaa | Brand | 15 | $309,869 | |
| Humira(Cf) Pen Adalimumab | Brand | 21 | $284,819 | |
| Dupixent Syringe Dupilumab | Brand | 67 | $258,630 | |
| Bimzelx Autoinjector Bimekizumab-Bkzx | Brand | 15 | $219,812 | |
| Dupixent Pen Dupilumab | Brand | 49 | $195,814 | |
| Remicade Infliximab | Brand | 17 | $181,497 | |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | Brand | 22 | $120,451 | |
| Taltz Syringe Ixekizumab | Brand | 12 | $81,657 | |
| Rinvoq Upadacitinib | Brand | 12 | $73,071 |
The 10 drugs with the highest cost, of 36 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 60 billing codesPaid by Medicare
$243,846
Medicare patients
1,043
Services billed
5,255
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 61% | |
| Arthritis | 49% | |
| Ischemic heart disease | 26% | |
| Osteoporosis | 20% | |
| Diabetes | 19% | |
| Chronic kidney disease | 15% | |
| Cancer | 15% | |
| Depression | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 86 | 260 | $180 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 38 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| DUPIXENT |
|
$101,162 | 116 | — |
| Bimzelx |
|
$42,358 | 15 | — |
| TREMFYA |
|
$393 | — | — |
| SOTYKTU |
|
$334 | — | — |
| SKYRIZI |
|
$222 | 15 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 38 with PatronRecords
1,433 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.